Use of NF-kB Inhibition in Combination Therapy for Cancer
First Claim
Patent Images
1. A method of enhancing the cytotoxic effects of radiation therapy, comprising administering to a mammalian subject in need of said radiation therapy a therapeutically effective amount of NF-κ
- B inhibitor in conjunction with the administration of the radiation therapy whereby the cytotoxic effect of said radiation therapy is increased compared to that which would occur in the absence of NF-κ
B inhibitor.
2 Assignments
0 Petitions
Accused Products
Abstract
The use of NF-κB inhibitors to enhance the cytotoxic effects of chemotherapy or radiation therapy in the treatment of neoplastic conditions is described.
-
Citations
17 Claims
-
1. A method of enhancing the cytotoxic effects of radiation therapy, comprising administering to a mammalian subject in need of said radiation therapy a therapeutically effective amount of NF-κ
- B inhibitor in conjunction with the administration of the radiation therapy whereby the cytotoxic effect of said radiation therapy is increased compared to that which would occur in the absence of NF-κ
B inhibitor. - View Dependent Claims (2, 14, 16)
- B inhibitor in conjunction with the administration of the radiation therapy whereby the cytotoxic effect of said radiation therapy is increased compared to that which would occur in the absence of NF-κ
-
3-5. -5. (canceled)
-
6. A method of enhancing cytotoxicity in a mammalian subject treated with radiation therapy, comprising administering to the mammalian subject a therapeutically effective amount of NF-κ
- B inhibitor in conjunction with the administration of the radiation therapy, whereby the cytotoxic effect of said radiation therapy is increased compared to that which would occur in the absence of NF-κ
B inhibitor. - View Dependent Claims (7, 15, 17)
- B inhibitor in conjunction with the administration of the radiation therapy, whereby the cytotoxic effect of said radiation therapy is increased compared to that which would occur in the absence of NF-κ
-
8-13. -13. (canceled)
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeAlbert Baldwin, Cun-Yu Wang, James Cusack, Marty Mayo
-
Original AssigneeAlbert Baldwin, Cun-Yu Wang, James Cusack, Marty Mayo
-
InventorsWang, Cun-Yu, Baldwin, Albert, Cusack, James, Mayo, Marty
-
Granted Patent
-
Time in Patent OfficeDays
-
Field of Search
-
US Class Current424/1.110
-
CPC Class CodesA61K 2300/00 Mixtures or combinations of...A61K 31/4745 condensed with ring systems...A61K 31/70 Carbohydrates; Sugars; Deri...A61K 38/1709 from mammalsA61K 38/191 Tumor necrosis factors [TNF...
